BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24417966)

  • 1. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.
    Wang BZ; Gill HS; He C; Ou C; Wang L; Wang YC; Feng H; Zhang H; Prausnitz MR; Compans RW
    J Control Release; 2014 Mar; 178():1-7. PubMed ID: 24417966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
    Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
    J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.
    Wang Y; Li S; Dong C; Ma Y; Song Y; Zhu W; Kim J; Deng L; Denning TL; Kang SM; Prausnitz MR; Wang BZ
    ACS Appl Bio Mater; 2021 Jun; 4(6):4953-4961. PubMed ID: 34179728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
    Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
    Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
    Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
    J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine.
    Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z
    Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection.
    Kim YC; Lee SH; Choi WH; Choi HJ; Goo TW; Lee JH; Quan FS
    J Drug Target; 2016 Dec; 24(10):943-951. PubMed ID: 26957023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
    Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.
    Wang L; Wang YC; Feng H; Ahmed T; Compans RW; Wang BZ
    Biomed Res Int; 2013; 2013():686549. PubMed ID: 23984396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
    Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
    PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
    Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
    PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.
    Yin Y; Li B; Zhou L; Luo J; Liu X; Wang S; Lu Q; Tan W; Chen Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1933-1942. PubMed ID: 32811334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.